Currently, in AML patients submitted to allo-HSCT, high TIGIT expression at engraftment has been associated with a reduced number of NK cells in the BM and in the post-transplant follow-up high TIGIT expression is associated with a reduced incidence of aGVHD, poor OS, and progression-free survival (PFS) [69]. Here, TIGIT is linked to acute myeloid leukemia.